# GLCCI1

## Overview
The GLCCI1 gene encodes the glucocorticoid-induced 1 protein, which plays a pivotal role in modulating cellular responses to glucocorticoids, particularly in the context of apoptosis and inflammation. This protein is primarily recognized for its antiapoptotic functions in thymic T cells, where it is upregulated by the glucocorticoid receptor pathway to protect these cells from glucocorticoid-induced apoptosis (Kiuchi2019GLCCI1). GLCCI1 interacts with key proteins such as LC8 and PAK1, influencing apoptotic pathways and glucocorticoid signaling (Kiuchi2019GLCCI1). Beyond its role in immune cells, GLCCI1 is implicated in maintaining podocyte structure in the kidneys and is associated with the PI3K signaling pathway (Kim2016GLCCI1). Clinically, variations in the GLCCI1 gene have been linked to differential responses to inhaled corticosteroids in asthma patients, highlighting its significance in personalized medicine (Salhi2019GLCCI1; Izuhara2014GLCCI1). Additionally, novel genetic fusions involving GLCCI1 have been identified, suggesting broader implications in kinase signaling and disease (Green2022Novel).

## Function
The GLCCI1 gene encodes a protein that plays a crucial role in protecting thymic T cells from glucocorticoid-induced apoptosis. This protein is upregulated by the glucocorticoid receptor (GC-GR) pathway and functions as an antiapoptotic molecule, particularly in double-positive (DP) T cells, which are highly sensitive to glucocorticoid-induced apoptosis (Kiuchi2019GLCCI1). GLCCI1 interacts with proteins such as LC8 and PAK1, influencing apoptotic pathways by modulating phosphorylation events. It competes with LC8 as a substrate for PAK1, potentially affecting LC8 dimerization and reducing the expression of Bim, a proapoptotic protein (Kiuchi2019GLCCI1).

In addition to its role in T cells, GLCCI1 is associated with the PI3K signaling pathway in podocyte foot processes, which are essential for kidney filtration. In diabetic conditions, GLCCI1 expression is reduced, but it can be restored with PI3K inhibitors, suggesting its involvement in maintaining podocyte structure and function (Kim2016GLCCI1). Overall, GLCCI1 is a key player in cellular processes that regulate apoptosis and maintain cellular homeostasis in response to glucocorticoid signaling.

## Clinical Significance
Mutations and alterations in the GLCCI1 gene have been linked to various clinical conditions, particularly asthma. The GLCCI1 gene is associated with the response to inhaled corticosteroids (ICS) in asthma patients. Specific single nucleotide polymorphisms (SNPs) such as rs37973 have been identified as influencing the effectiveness of ICS therapy. The GG genotype of rs37973 is associated with a significant decline in pulmonary function, as measured by forced expiratory volume in one second (FEV1), in patients undergoing long-term ICS treatment (Izuhara2014GLCCI1). This genotype is also linked to a higher risk of developing severe asthma (Salhi2019GLCCI1).

In a Tunisian population, the rs37973 and rs37972 SNPs in GLCCI1 were associated with increased asthma susceptibility and severity, with the G allele of rs37973 linked to a poorer response to ICS (Salhi2019GLCCI1). Additionally, GLCCI1 expression is involved in airway remodeling and inflammation in asthma, with its overexpression reducing airway resistance and collagen deposition in a mouse model (Xun2021GLCCI1).

A novel GLCCI1-BRAF fusion has been identified in a case of pheochromocytomatosis, suggesting a role in kinase signaling dysregulation (Green2022Novel).

## Interactions
GLCCI1 interacts with several proteins, playing a significant role in cellular processes related to apoptosis and glucocorticoid signaling. It binds to the dynein light chain LC8, a protein involved in the apoptotic pathway, through a conserved sequence at amino acid residues 200-204. This interaction is crucial for LC8 dimerization, which affects various cellular events, including apoptosis (Kiuchi2019GLCCI1). GLCCI1 also interacts with p21-activated kinase 1 (PAK1), a serine/threonine kinase. PAK1 phosphorylates GLCCI1, but GLCCI1 reduces the phosphorylation of both LC8 and PAK1, indicating it interferes with PAK1-mediated phosphorylation of LC8 (Kiuchi2019GLCCI1).

In the context of glucocorticoid signaling, GLCCI1 facilitates the binding between the glucocorticoid receptor (GR) and GR-interacting protein 1 (GRIP1). It inhibits GRIP1's recruitment to interferon regulatory factors IRF1 and IRF3, which are transcription factors involved in inflammatory signaling. This modulation is crucial for maintaining the anti-inflammatory effects of glucocorticoids, particularly in conditions like asthma (Hu2021GLCCI1; Ananthapadmanabhan2023Insights). These interactions highlight GLCCI1's role as a modulator of both apoptotic and glucocorticoid signaling pathways.


## References


[1. (Green2022Novel) Benjamin L Green, Robert R C Grant, Christopher T Richie, Bishwanath Chatterjee, Michelly Sampaio De Melo, Frederic G Barr, Karel Pacak, Sunita K Agarwal, and Naris Nilubol. Novel glcci1-braf fusion drives kinase signaling in a case of pheochromocytomatosis. European Journal of Endocrinology, 187(1):185–196, June 2022. URL: http://dx.doi.org/10.1530/eje-21-0797, doi:10.1530/eje-21-0797. This article has 2 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1530/eje-21-0797)

[2. (Kiuchi2019GLCCI1) Zentaro Kiuchi, Yukino Nishibori, Satoru Kutsuna, Masashi Kotani, Ichiro Hada, Toru Kimura, Toshiyuki Fukutomi, Daisuke Fukuhara, Noriko Ito-Nitta, Akihiko Kudo, Takanobu Takata, Yasuhito Ishigaki, Naohisa Tomosugi, Hirotoshi Tanaka, Satsuki Matsushima, Shinya Ogasawara, Yoshiaki Hirayama, Hiromu Takematsu, and Kunimasa Yan. Glcci1 is a novel protector against glucocorticoid‐induced apoptosis in t cells. The FASEB Journal, 33(6):7387–7402, March 2019. URL: http://dx.doi.org/10.1096/fj.201800344RR, doi:10.1096/fj.201800344rr. This article has 22 citations.](https://doi.org/10.1096/fj.201800344RR)

[3. (Izuhara2014GLCCI1) Y. Izuhara, H. Matsumoto, Y. Kanemitsu, K. Izuhara, Y. Tohda, T. Horiguchi, H. Kita, K. Kuwabara, K. Tomii, K. Otsuka, M. Fujimura, N. Ohkura, K. Tomita, A. Yokoyama, H. Ohnishi, Y. Nakano, T. Oguma, S. Hozawa, T. Nagasaki, I. Ito, T. Oguma, H. Inoue, T. Tajiri, T. Iwata, J. Ono, S. Ohta, M. Tamari, T. Hirota, T. Yokoyama, A. Niimi, and M. Mishima. <scp>glcci</scp>1 variant accelerates pulmonary function decline in patients with asthma receiving inhaled corticosteroids. Allergy, 69(5):668–673, March 2014. URL: http://dx.doi.org/10.1111/all.12400, doi:10.1111/all.12400. This article has 37 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1111/all.12400)

[4. (Xun2021GLCCI1) Qiufen Xun, Jiulong Kuang, Qing Yang, Wei Wang, and Guofeng Zhu. Glcci1 reduces collagen deposition and airway hyper‐responsiveness in a mouse asthma model through binding with wd repeat domain 45b. Journal of Cellular and Molecular Medicine, 25(14):6573–6583, May 2021. URL: http://dx.doi.org/10.1111/jcmm.16658, doi:10.1111/jcmm.16658. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/jcmm.16658)

[5. (Kim2016GLCCI1) Sang-Hoon Kim, Hyun-Jung Kim, and Chan-Wha Kim. Glcci1 is a novel component associated with the pi3k signaling pathway in podocyte foot processes. Experimental &amp; Molecular Medicine, 48(5):e233–e233, May 2016. URL: http://dx.doi.org/10.1038/emm.2016.28, doi:10.1038/emm.2016.28. This article has 15 citations.](https://doi.org/10.1038/emm.2016.28)

[6. (Ananthapadmanabhan2023Insights) Varsha Ananthapadmanabhan, Kathryn H. Shows, Amanda J. Dickinson, and Larisa Litovchick. Insights from the protein interaction universe of the multifunctional “goldilocks” kinase dyrk1a. Frontiers in Cell and Developmental Biology, October 2023. URL: http://dx.doi.org/10.3389/fcell.2023.1277537, doi:10.3389/fcell.2023.1277537. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcell.2023.1277537)

[7. (Salhi2019GLCCI1) Mariem Salhi, Oussama Lahmar, Marwa Ouled Salah, Ivana Banić, Bao Binghao, Waqar Malik, Kamel Hamzaoui, Mirjana Turkalj, and Agnes Hamzaoui. Glcci1 and stip1 variants are associated with asthma susceptibility and inhaled corticosteroid response in a tunisian population. Journal of Asthma, 58(2):197–206, September 2019. URL: http://dx.doi.org/10.1080/02770903.2019.1666867, doi:10.1080/02770903.2019.1666867. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/02770903.2019.1666867)

[8. (Hu2021GLCCI1) Xinyue Hu, Shuanglinzi Deng, Lisha Luo, Yuanyuan Jiang, Huan Ge, Feifei Yin, Yingyu Zhang, Daimo Zhang, Xiaozhao Li, and Juntao Feng. Glcci1 deficiency induces glucocorticoid resistance via the competitive binding of irf1:grip1 and irf3:grip1 in asthma. Frontiers in Medicine, August 2021. URL: http://dx.doi.org/10.3389/fmed.2021.686493, doi:10.3389/fmed.2021.686493. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmed.2021.686493)